PYRIDOPYRIMIDINE COMPOUNDS ACTING AS DOUBLE INHIBITORS OF mTORC 1/2 Russian patent published in 2022 - IPC C07D471/04 C07D519/00 A61K31/5377 A61K31/5383 A61K31/5386 A61P35/00 A61P35/02 

FIELD: pharmaceutics.

SUBSTANCE: invention relates to the field of organic compounds. A compound of the formula (IV), its pharmaceutically acceptable salt, or its stereoisomer is proposed, where R₁ is H; R₂ is Me; alternatively, R₁, R₂ and N atom in morpholine ring form 5-6-element heterocycloalkyl; R₃ is selected from NH₂, 5-6-element heteroaryl and n is selected from 1 and 2; ring A is selected from phenyl, 9- and 10-element heteroaryl; R₄ and R₅ are H; alternatively, R₄ and R₅ are joined together to form 5-6-element heterocycloalkyl; D₁, D₂, D₃ and D₄ are respectively selected from a single bond, -CH₂-, -CH₂CH₂- and -O-, and at least one of D₁, D₂, D₃ and D₄ is not a single bond, where -CH₂- or -CH₂CH₂- is optionally substituted with R, and R is equal to 1; D₅, D₆, D₇ and D₈ are respectively selected from a single bond, -CH₂-, -O- and -NH-, and at least one of D₅, D₆, D₇ and D₈ is not a single bond, where -CH₂- is optionally substituted with R, and R is equal to 1 or 2, -NH- is optionally substituted with R; T₁ is selected from CH and N; T₂ is selected from -CH₂-, -NH-, -O-, -S- and -C(=O)NH-, where -CH₂ is optionally substituted with R, and R is equal to 1 or 2, -NH is optionally substituted with R; where R is respectively selected from CF₃, F, OH, C_1-3alkyl and C_1-3alkoxy; 5-6-element heteroaryl, 9-element heteroaryl and 10-element heteroaryl respectively contain 1, 2 or 3 heteroatoms or heteroatomic groups independently selected from -O-, -NH- and N. Specific compounds, a pharmaceutical composition, and the use of a compound of the formula (IV) for the preparation of a drug for the treatment of breast cancer are also proposed.

EFFECT: production of pyridopyrimidine compounds that have a double inhibitory activity against mTOR1/2.

17 cl, 9 tbl, 56 ex